Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

67.36 USD -1.02 (-1.49%)
Official Closing Price Updated: 4:52 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Axsome Thera

< Previous 1 2 3 4 5 6 7 Next >
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder
From GlobeNewswire News Releases
Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney?
InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS. 
From PR Newswire
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
From GlobeNewswire News Releases
Axsome Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting
From GlobeNewswire News Releases
Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually
From GlobeNewswire News Releases
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020
From GlobeNewswire News Releases
Thinking about trading stocks or options in Apple, Axsome Therapeutics, Walt Disney, Royal Caribbean Cruises, or Trade Desk?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, DIS, RCL, and TTD. 
From PR Newswire
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation
From GlobeNewswire News Releases
Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine
From GlobeNewswire News Releases
NetworkNewsAudio – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Focused on Providing Mushroom-Infused Wellness Products
From InvestorBrandNetwork
Medical Mushroom Companies Expand as People Seek New Mental Health Treatments
From InvestorBrandNetwork
Medical Mushroom Companies Expand as People Seek New Mental Health Treatments
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Medical Mushroom Companies Expand as People Seek New Mental Health Treatments
NetworkNewsWire Editorial Coverage 
From PR Newswire
Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications
From GlobeNewswire News Releases
Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
From GlobeNewswire News Releases
Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Companies Around the World Broaden Offerings to Enhance Mental Health, Wellness Options
From InvestorBrandNetwork
Companies Around the World Broaden Offerings to Enhance Mental Health, Wellness Options
NetworkNewsWire Editorial Coverage 
From PR Newswire
Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer
From GlobeNewswire News Releases
Axsome Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
From GlobeNewswire News Releases
Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine
From GlobeNewswire News Releases
Axsome Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
From GlobeNewswire News Releases
Global Brain Tumor Drugs Market Expected To Exceed $3 Billion Through 2022
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Brain Tumor Drugs Market Expected to Exceed $3 Billion Through 2022
Financialnewsmedia.com News Commentary 
From PR Newswire
Thinking about buying stock in Apple, Axsome Therapeutics, Crocs, Lululemon Athletica, or Tilray?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, CROX, LULU, and TLRY. 
From PR Newswire
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
From GlobeNewswire News Releases
Thinking about buying stock in Advanced Micro Devices, Axsome Therapeutics, FuelCell Energy, Microsoft, or Nio?
InvestorsObserver issues critical PriceWatch Alerts for AMD, AXSM, FCEL, MSFT, and NIO. 
From PR Newswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.